<DOC>
	<DOCNO>NCT00385593</DOCNO>
	<brief_summary>This study intend extend knowledge Symbicort Single Inhaler Therapy general set order assess real-life impact introduce new treatment concept . The study compare Symbicort Single Inhaler Therapy concept conventional stepwise treatment regimen accord investigator 's judgement patient present symptom inhale glucocorticosteroids ( GCS ) treatment require already treatment combination inhale long-acting B2 agonist ( LABA ) .</brief_summary>
	<brief_title>Symbicort Single Inhaler Therapy vs Conventional Best Practice Treatment Persistent Asthma Adults</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Minimum 3 month history asthma , diagnose accord American Thoracic Society ( ATS ) definition ( 9 ) . Prescribed inhale GCS dose 400μg/day budesonide ( equivalent ) within approve label relevant drug last 3 month prior Visit 1 . Either daily maintenance treatment inhale GCS LABA daily treatment inhale GCS alone ( i.e . without LABA ) A history suboptimal asthma control month prior enrolment judged investigator Use ≥3 inhalation need medication symptom relief last 7 day enrolment Previous treatment Symbicort Single Inhaler ; Use bblocking agent , include eyedrops oral GCS maintenance treatment . Known suspected hypersensitivity study therapy excipients . A history smoking ≥ 10 pack year . Asthma exacerbation require change asthma treatment last 14 day prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>